Our patented public hands free door handle – The SanitGrasp – is exploding in sales. We are prepared to help the health of all public facilities” stated Mathew Fulkerson owner of the SanitGrasp patents.

ALPHARETTA, Ga. (PRWEB)
March 20, 2020

SanitGrasp, the internationally patented hands-free door handle, is being recognized as the door handle that best satisfies health and safety concerns that have recently been raised due to the current World Wide health concerns. This door handle is in the shape of a “J”, thereby allowing a person to open a door with their closed fist or wrist. The SanitGrasp is designed for all public facilities allowing people to avoid germs on the public restroom door pull handle.

The SanitGrasp has been identified as a major improvement to public and private facilities throughout the US, since 2005. However, due to the recent developments the SanitGrasp is in significant demand. “We have received a substantial increase in orders. In the initial years we would see a spike due to certain strains of Influenza, but due to much hard work we are a specified product within many facilities and we have been able manage our demand. But this is much different we have been slammed with orders for corporations, Government offices, and public facilities.” stated Matthew Fulkerson, inventor of the SanitGrasp and owner of Fulkerson, LLC.

The SanitGrasp was engineered to easily remove an existing door pull handle and use the same screw holes to add the SanitGrasp in place of the old door handle. What a simple solution to the old problem, how do I exit the restroom without touching that nasty door handle.

Additional information is available at http://www.sanitgrasp.com or by contacting Fulkerson, LLC at 800-351-6435.

Share article on social media or email:

“We are proud to name Dr. Craig Smith as a UroLift Center of Excellence and provider of care for men with enlarged prostate symptoms using the UroLift System treatment,” said Dave Amerson

PLEASANTON, Calif. (PRWEB)
March 20, 2020

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Craig Smith, M.D., DuPage Medical Group in Chicago, IL, has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Smith has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“We are proud to name Dr. Craig Smith as a UroLift Center of Excellence and provider of care for men with enlarged prostate symptoms using the UroLift System treatment,” said Dave Amerson, president of the Teleflex Interventional Urology business unit. “The UroLift System is a safe and effective treatment that allows physicians to treat men in-office under local anesthesia, so they can experience lasting symptom relief within days after receiving treatment.”

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

# # #

For Teleflex Incorporated:

Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504 nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

1. Roehrborn, J Urology 2013 LIFT Study

2.McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email:

To break a transmission chain, fast access is needed. These tools offer a tool for action, rather than waiting on texts and doctor’s office staff.

ARLINGTON, Va. (PRWEB)
March 20, 2020

Demand for testing has gone from a healthcare industry topic to a national crusade in weeks with the onset of COVID-19. High-throughput tests have been approved by the U.S. Food and Drug Administration (FDA) for use in the U.S. for the detection of SARS-CoV-2, the virus behind the disease. But for true intervention in doctors offices — or even airports, many see so-called “point-of-care” (POC) IVD tests as the ideal solution.

A new report on worldwide point-of-care markets from IVD market researcher Kalorama Information has been released amid the coronavirus outbreak. The report has markets for all kinds of near-patient testing — everything from self-testing for glucose to rapid HIV tests to cardiac marker tests. Yet the focus in recent weeks has been on tests for COVID-19. Point-of-care tests are tests designed to be portable enough and fast enough to be useful during an office visit or in a decentralized location within a hospital or clinic.

“To break a transmission chain, fast access is needed. These tools offer a tool for action, rather than waiting on texts and doctor’s office staff,” said Bruce Carlson, publisher of Kalorama Information.

Kalorama publishes a report each year on POC markets and has just released its 2020 version: https://kaloramainformation.com/product/the-worldwide-market-for-point-of-care-poc-diagnostics-7th-edition/.

In terms of actual tests for coronavirus tests, there are no U.S. approvals at the time of writing, but products are in development. Molecular POC (mPOC) tests make the most sense because the threat is a virus and can be identified using the gold standard of reverse transcription polymerase chain reaction (RT-PCR). Point-of-care tests are currently used for flu and step tests, including systems by Abbott (ID NOW), Roche (Liat), and Cepheid (Xpert Xpress).

mPOC-maker Cepheid says it is developing an automated molecular test for the qualitative detection of SARS-CoV-2. And Cepheid says it will try to utilize its tens of thousands of existing instrument placements. “By leveraging the design principles of our current Xpert Xpress Flu/RSV cartridge technology, in which multiple regions of the viral genome are targeted to provide rapid detection of current and future pandemic coronavirus strains, we are developing a test that can be applied in multiple settings where actionable patient management information is needed quickly,” the company said.

Singapore POC maker Credo Diagnostics Biomedical announced this week that it has obtained the CE mark in Europe for an assay to detect SARS-CoV-2. The test runs on the firm’s platform, called VitaPCR, and the company said it uses PCR and runs the test in 20 minutes. The system needs minimal operator training to run and involves no additional equipment, according to Credo. The company says the VitaPCR SARS-CoV-2 Assay is now also pending Emergency Use Authorization from the FDA and Emergency Use Listing from the World Health Organization.

While not as fast as immunoassays, the mPOC systems typically use isothermal amplification to achieve much faster turnaround than the regular lab-based RT-PCR tests. This is one of their biggest strengths, along with low system cost and portability; however, these can often have a several-fold higher cost per sample compared with RT-PCR performed in a centralized lab due to the small proprietary systems requiring specific cartridges and consumables. The following are some additional examples of molecular diagnostic systems and assays including POC and other technologies which are available or under development:

• 
  Aldatu Biosciences – PANDAA qDx SARS-CoV-2
• Becton Dickinson (BD) – BD and BioGX submitted for EUAs on BD Max platform- BGI/ Pathomics Health – Fluorescent RT-PCR kit (CE marked); 2019-nCoV PMseq Kit
• Bio-Rad – standards – synthetic COVID-19 RNA transcripts and human genomic DNA
• bioMerieux/ BioFire Defense – FilmArray, BioFire COVID-19 Test
• Biomeme – Go Strips for COVID-19
• BIONEER Corporation – AccuPower 2019-nCoV
• Caspr Biotech – Phantom 1.0 Dx, disposable test usingCRISPR
• Cepheid – Test in development for Xpert Xpress system announced; partnership for Sherlock Biosciences’ CRISPR-based SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) engineering biology platform, to design tests to run on Cepheid’s GeneXpert systems
• CerTest Biotec – VIASURE 2019-nCoV Real Time PCR Kit (CE mark for BD Max platform)
• Co-Diagnostics – Logix Smart Coronavirus Disease 2019 (COVID-19) Test; single step rRT-PCR (CE mark)
• Coyote Bioscience – Mini8 Portable Molecular Diagnostic QPCR Station (CFDA approved)
• Credo Diagnostics Biomedical – VitaPCR platform, COVID-19 assay (CE mark)
• Curetis/ OpGen/ BGI – RTPCR test kit for SARS-CoV2 (CE mark)
• Diagnostics for the Real World Ltd – SAMBA II COVID-19 Test
• GenMark – ePlex SARS-CoV-2 test; sample-to-answer system based on competitive DNA hybridization and electrochemical detection technology (RUO, with EUA submitted)
• HiberGene – HG Swift, can use battery power, pursuing Fast Track Emergency Use in China
• Integrated DNA Technologies (Danaher) – 2019-nCoV CDC EUA Kit
• Jiangsu Qitian Gene Biotechnology Co., Ltd. – Fluorescent RAA Detection for 2019-nCoV
• LabCorp – COVID-19 reverse transcription polymerase chain reaction (RT-PCR) test (EUA issued)
• LGC Biosearch – primer and probe kits for CDC Real-Time RT-PCR Diagnostic Panel
• MiCo Biomed Co. Ltd – VERI-QTM PCR 316 COVID-19 detection system
• Mobidiag – Novodiag COVID-19 + InfA/B – multiplex test for coronavirus and influenza
• Molbio – TrueLab, Truenat SARS CoV-2 – TruePrep and TrueNAT instruments
• Mologic – battery powered point-of-need diagnostic test
• Novacyt – qPCR (CE mark)
• OnSiteGene – Peak V
• Pinpoint Science – SARS-Cov-2 test in partnership with Analog Devices
• Qiagen – QIAstat-Dx, Respiratory Panel 2019-nCoV
• QuantuMDx – Q-POC
• RainSure Bio – DropX-2000 Digital PCR System, RainSure COVID-19 dPCR Detection Kit
• Randox Laboratories Ltd – Extended Coronavirus Array
• Seegene – Allplex 2019-nCoV assay (CE mark)
• Sentinel Diagnostics – Stat-NAT COVID-19 assay
• SolGent – DiaPlexQ Novel Coronavirus (2019-nCoV) Detection Kit (CE mark)
• Twist Bioscience – NGS-based target capture for SARS-CoV-2 detection and screening
• Ubiquitome – Liberty16, open mobile real time PCR system with 2-3 hour battery life

In addition to direct tests for SARS-CoV-2, Kalorama expects demand for flu tests to increase due to “rule-out” testing.

Right now, molecular is the focus for the current pandemic, but immunoassays also are in development. Molecular tests generally analyze the viral RNA in patient throat/nasal swabs, but there are other POC testing methods that use immunoassays to detect the patient’s COVID-19 antibodies in blood or serum. It appears there are roles for both mPOC and immunoassay POC tests as there are trade-offs between the two. Immunoassays generally suffer from a high rate of false negatives (low sensitivity), with some rare exceptions.

Nonetheless, immunoassays can have comparable specificity and a varying combination of lower cost, faster turnaround, greater portability, and, thus, advantages in the context of larger-scale population surveillance, screening, and triaging of patients in outbreak situations.

About Kalorama Information

For more than 30 years, Kalorama Information has been a leading publisher of market research in healthcare areas, including in vitro diagnostics (IVD), imaging, biotechnology, healthcare, medical devices, and pharmaceuticals.

Share article on social media or email:

The Therapeutic Education Program at New Alliance Academy Results in the Greater Likelihood of Students Pursuing Post-Secondary Education

“The programs offered at New Alliance Academy give our students a deeper understanding of themselves while setting them up for success on their journey to adulthood.” – New Alliance Academy Administration

PARAMUS, N.J. (PRWEB)
March 20, 2020

New Alliance Academy provides its students with the life skills and tools needed to have a successful and productive life, as well as encourages those interested in pursuing tertiary studies to achieve their goal. One of the most frequently asked questions by parents and students is whether adolescents who attend the school have a good chance of progressing into college.

New Alliance Academy is proud to report that data collected over a 10 year period, show that the percentage of graduates who plan to attend a two or four year college is double the national average for students exiting similar schools.

About

New Alliance Academy in Paramus, NJ is a high school for teenagers who experience acute psychological distress. New Alliance Academy provides a full educational curriculum that addresses the emotional and academic needs of its students in a day school setting. The school integrates educational and ancillary therapeutic services, expertly crafted and delivered in one location. These therapeutic services are designed to eventually facilitate the adolescent’s return to a least restrictive educational setting as soon as they are ready. Students gain a deeper understanding of themselves by receiving the tools they need to move forward in their education and in life.

Share article on social media or email:

WCG CenterWatch

FALLS CHURCH, Va. (PRWEB)
March 20, 2020

With ICH E8(R1) set to be adopted in June 2020, how one plans, designs and conducts clinical trials will look different than they do today. Be ready to implement the new guidelines.

The Revised ICH E8: A Guide to New Clinical Trial Requirements management report shows readers how to leverage the revised guidelines’ quality-by-design approaches, expanded study designs and data source considerations. With this knowledge, one can adapt, continuing to provide a quality-driven framework that leads to efficient and timely decision making, and ultimately to improved access to safe and effective drugs. This management report will:

• 
  Explain the scope and general principles of the ICH E8(R1) guideline
• Describe the impact on current research practices that could influence SOPs, procedures, processes and documentation
• Describe the framework and approaches for identifying critical-to-quality factors
• Identify clinical development areas that may be impacted by the adoption of the ICH E8(R1) guideline and approaches for compliance

Prepare for ICH E8(R1) now, June is only a few months away.

Management Report Details:

The Revised ICH E8:

A Guide to New Clinical Trial Requirements

A CenterWatch Book

https://www.centerwatch.com/products/category/1105-books/product/435-the-revised-ich-e8-a-guide-to-new-clinical-trial-requirements-pdf

Management Report PDF:

$397

Easy Ways to Order:

Online: https://www.centerwatch.com/products/category/1105-books/product/435-the-revised-ich-e8-a-guide-to-new-clinical-trial-requirements-pdf

By phone: 888.838.5578 or 703.538.7600

About CenterWatch:

Founded in 1994, CenterWatch is a trusted source and global destination for clinical trials information for both professionals and patients. CenterWatch provides proprietary data and information analysis on clinical trials through a variety of newsletters, books, databases, and information services used by pharmaceutical and biotechnology companies, CROs, SMOs, and investigative sites involved in the management and conduct of clinical trials. As a pioneer in publishing clinical trials information, CenterWatch was the first Internet site to publish detailed information about active clinical trials that could be accessed by patients and their advocates.

Share article on social media or email:

MOBILE, Ala. (PRWEB)
March 19, 2020

As COVID-19 spreads across the nation, the Centers for Disease Control and other healthcare experts call for us to practice social distancing and, in some cases, self-quarantine to help stop the spread of the coronavirus. However, social distancing and quarantine can be especially difficult for people who have underlying mental health issues.

Cindy Gipson, Ph.D., serves as the assistant director of intensive services for AltaPointe Health and offers the following tips for staying connected in positive ways during these uncertain times.

• 
  Tune out media that can produce anxiety or fear. It is okay to stay informed but do not spend more than 30 minutes a day on news media. Find out what you need to know to be safe then tune out.
• Tune in to your support system. Reach out to family and friends by text or phone so that you stay connected and share information about your day, your hobbies, or your concerns.
• Tune out, negative people. You don’t need doom and gloom right now. Keep it positive or keep it moving!
• Tune in to your resources. If you need more support than you can get from friends and family, reach out to your mental health professionals. We are still here to make sure you get what you need, and there are many ways we can help by phone.
• Remember, YOU control the ability to tune in or tune out. Focus on the positive and do something that makes you feel productive at home and take comfort in talking with friends and family by phone. We are going to get through with the support of each other!

AltaPointe Health is Alabama’s largest and most comprehensive health and human services organization and psychiatric hospital system. It is the second largest in the southeastern US serving Mobile, Baldwin, and Washington counties in south Alabama and Clay, Coosa, Randolph, and Talladega counties to the north. Each year it provides mental health, substance abuse, and intellectual disability services to more than 35,000 children and adults.

Share article on social media or email: